Treatment with LY3298176, a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (GLP-1) receptor agonist, resulted in better glucose control than dulaglutide, a GLP-1 receptor agonist, reported a phase 2 trial in the Lancet.
The 318 patients with type 2 diabetes were randomly assigned to 6 treatment groups: once-weekly subcutaneous LY3298176 (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.
Slomski A. Dual Receptor Agonist for Type 2 Diabetes. JAMA. 2018;320(24):2521. doi:10.1001/jama.2018.20160
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: